Johnson & Johnson: Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength ...
Frontiersman

Governor proclaims Red Ribbon Week, encourages education about drug use prevention in schools

Alaska has been inundated with the scourge of drug overdoses, with the state ranking among the highest in the country for overdoses. There are no official reports for 2024 yet, ...
The American Journal of Managed Care

Weighing ICS Benefits vs Long-Term Systemic Side Effects in COPD: Sara Assaf, MD

Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation ...
Neurology Advisor

FDA Clears Blood Test for Early Detection of Amyloid Pathology

The FDA has cleared the Elecsys pTau181 test as an aid in early detection of amyloid pathology in the primary care setting for adults aged 55 years and older presenting with signs, symptoms or ...